Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Submit Guest Post

Small antiviral study hints at possible benefit in Long Covid

A small study found a five-day intravenous treatment benefitted fatigue and quality of life.

Antiviral

The next stage would be to rigorously test the treatment in a larger study to establish effectiveness

iStock

An experimental antiviral treatment for Long Covid has shown encouraging results in a clinical trial, with researchers suggesting larger studies to establish whether or not it can effectively relieve symptoms.

The £1.2 million ERASE trial, led by the University of Derby and Loughborough University and managed by the University of Plymouth’s Peninsula Clinical Trials Unit, investigated whether an intravenous antiviral could be used to treat people living with Long Covid.


Researchers found the treatment regimen could be successfully delivered, with participants completing the clinical assessments required to evaluate its safety and feasibility. The small study involved 73 patients who received the treatment over five consecutive days.

Exploratory assessments also indicated improvements in fatigue, quality of life, functional capacity and walking distance, with most participants reporting reduced fatigue and better quality of life.

However, the trial was not designed to establish whether the treatment caused these improvements or whether it is effective in treating Long Covid.

A larger trial would be the next step

Professor Mark Faghy, Visiting Professor at the University of Derby and Professor of Clinical Exercise Science at Loughborough University who led the study, said: “These findings are an important step forward in our research into potential treatments for Long Covid and we have shown that it is possible to deliver this intravenous antiviral treatment and undertake the assessments needed to evaluate it in people with Long Covid”.

Faghy added: “While ERASE was not designed to tell us whether the treatment caused those changes or whether it works, the next stage would be to rigorously test the treatment in a larger study to establish its effectiveness”.

Dr Tom Bewick, principal investigator for UHDB on this study, said: “We are proud to participate in the ERASE-Long Covid study in which over 50 Long Covid sufferers in Derbyshire were selected to receive a five-day course of antiviral Treatment at the Royal Derby Hospital. Following the successful delivery of this pilot, it is the goal to expand this research in the future in a larger randomised trial”.

Professor David Strain, clinician and study co-author from the University of Exeter, said: “We’re still seeing large numbers of people who are debilitated by Long Covid in clinics. Our study is a promising step to indicate that the specific antiviral may offer some relief from symptoms and we now need confirmation in much larger clinical trials to evaluate its effectiveness”.

Strain advised people living with Long Covid to speak to their GP and follow clinical guidance.

More than two million people in the UK are estimated to be living with Long Covid, with symptoms including extreme fatigue, breathlessness, palpitations and brain fog.

The ERASE trial began in September 2024 and involved clinical teams from University Hospitals of Derby and Burton NHS Foundation Trust and Royal Devon University Healthcare NHS Foundation Trust.